A medical worker fills a syringe with AstraZeneca vaccine at Santa Caterina da Siena – Amendola secondary school in Salerno on March 13, 2021 in Salerno, Italy.
Francesco Pecoraro | Getty Images News | Getty Images
LONDON – Public preference for the from AstraZeneca and the University of Oxford has fallen since reports have surfaced suggesting it may be linked to some cases of unusual blood clotting events.
An April study of nearly 5,000 adults in the UK, with Covid vaccine uptake high and the vaccination program well established, found that public preference for the AstraZeneca Covid vaccine has declined since March and there is a belief that that he caused blood clots to have increased.
The UK academic study found that 17% of the public now say they would prefer the AstraZeneca vaccine if they had a choice – up from 24% towards the end of March.
And 23% of people now believe the AstraZeneca vaccine causes blood clots – up from 13% in March. However, the public are still the most likely to say that this claim is false (39%) or that they don’t know if it is true (38%).
The study, conducted April 1–16 by the University of Bristol, King’s College London, and the NIHR Health Protection Unit for Emergency Preparedness and Response, found a “big difference” in beliefs before and after MHRA ( UK Drug Regulator) announced on April 7th that there is a possible link between the vaccine and extremely rare blood clots.
The study found that 17% of respondents in the first week of this month thought this claim was true, compared with 31% who were asked about it.
Clinical data showing the vaccine have been published since its first publication had an average effectiveness rate of 70% ((Subsequent studies in the US found an effectiveness rate of 79% and other attempts have shown The rate of effectiveness increases with the larger the gap between the first and second dose) The fate of the AstraZeneca vaccine is mixed to say the least.
One of the recent hurdles for the AstraZeneca vaccine was a small number of reports of unusual, sometimes fatal, blood coagulation events that occurred in post-vaccinating people in Europe in February, causing several countries to suspend use of the vaccine.
The UK and EU drug regulators (the UK medicines and health products regulator and the European Medicines Agency) looked into the reports and said while there was one Possible link between the vaccine and a low number of bleeding episodesThe benefits of the vaccine far outweighed the risks.
In addition, Experts tried to put the risk into contextThe number of reported rare cases of blood clotting with low platelets was roughly one case per 250,000 people vaccinated and one death in a million.
The UK is fortunate that it has traditionally received high levels of public support for vaccination. The vaccine preference survey found that, despite the growing belief that it was associated with blood clots, the AstraZeneca vaccine did not affect general confidence in vaccines in general. 81% say vaccines are safe, compared to 73% who said so in late 2020.
Similarly, perceptions of how vaccines work has changed: 86% say they are effective, up from 79% in November and December 2020.
However, surveys have shown that the public perception of the AstraZeneca vaccine has deteriorated in mainland Europe, and there is scattered evidence that people in the EU are using the AstraZeneca vaccine (referred to as the “Aldi” vaccine after the low-cost food chain because of its lower production costs and image) in favor of the coronavirus vaccine Pfizer-BioNTech, which also prevails with the introduction of EU vaccinations.
Hesitation to vaccinate can work both ways, it seems. A British doctor was reported in the Evening Standard newspaper in January Some of his patients had turned down the opportunity to receive the Pfizer vaccine, saying they would “wait for the English one.”